Big Pharma ramping up China R&D ops

Drug discovery and research activities have traditionally focused on diseases common in the U.S. and Europe. That is, after all, where the money is. But as Reuters expounds on in an analysis out today, China is grabbing an increasing share of the global R&D budget, with investigators launching a slew of new studies to help understand how to treat the country's huge population and tap into one of the fastest growing pharma markets on the planet. Report

Suggested Articles

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.

OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.